Biotech companies are slowing the growth in research and development spending even as profits rise worldwide. R&D spending grew by 5% last year, compared with 9% growth in 2011, and revenue grew by 8%. Companies increasingly look beyond regulatory approval and consider payer reimbursement potential when deciding whether to pursue drug candidates or acquisition targets, experts say.

Related Summaries